Endocrine resistance in breast cancer--An overview and update.
about
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersAnnexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast CancerPolymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation.COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.Oestrogen receptor negativity in breast cancer: a cause or consequence?Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.Anticipatory UPR Activation: A Protective Pathway and Target in Cancer.CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Introduction: Cancer Gene Networks.Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.Targeting protein quality control pathways in breast cancer.Time course study of the response to LPS targeting the pig immune gene networks.Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival.Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.The Dawning of Translational Breast Cancer: From Bench to Bedside.Luminal lncRNAs Regulation by ERα-Controlled Enhancers in a Ligand-Independent Manner in Breast Cancer Cells.Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.An in vitro model for the development of acquired tamoxifen resistance.Short SULF1/SULF2 splice variants predominate in mammary tumours with a potential to facilitate receptor tyrosine kinase-mediated cell signalling.Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.pH Responsive Polymer Micelles Enhances Inhibitory Efficacy on Metastasis of Murine Breast Cancer Cells.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast CancerCDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussionA novel somatic mutation of SIN3A detected in breast cancer by whole-exome sequencing enhances cell proliferation through ERα expressionNogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
P2860
Q28069856-130BCAC2-8925-45C9-8530-B146A45F3196Q28468360-FF6B0B5E-A09A-46F9-A5B4-898510EB93D3Q33591401-EECDB762-35A8-4F06-B66A-B0381FA9685DQ37033459-A3D1F4CD-85A6-4B30-ABE2-999460B5DC25Q37063329-422326AC-8DD6-41BB-9F37-8C8F44639087Q37321593-531AA66C-7D06-45B2-BD2E-14E196D83F69Q37529397-C15BC664-6CEE-4CA2-BDD8-B798884ED259Q37570653-757C3DD9-ED93-402B-A17A-2C5395DF14E8Q38432603-A4B0FB70-41E7-4A17-B068-555E23BE2A10Q38443838-F3654D6D-1346-4F81-8293-8C295D363BC7Q38649485-30747928-2E24-47DA-AC09-37A39D3C2914Q38707608-F938B324-DB0C-4516-B788-1888A2753E38Q38731611-75F36287-8D07-4F76-9A38-51DC5B5E41D4Q38847406-7D25C521-D315-4EF9-8EC6-FD1A7109D561Q38870640-241B6015-ABB4-4BE5-AF1A-448423B7E4A6Q39221896-B7DE462E-6865-4801-BC79-D8B5C21532EDQ41912547-D70E7128-8FB2-4E99-B086-068EFA03AD22Q42078197-E7D372B9-23C8-404D-A15F-CB848ADFC235Q42282812-A845439B-8D65-4E82-91FD-59A462A4FBE5Q46087491-7152948E-8309-4D3E-8DCA-9739F7F390CAQ47095455-5B0CF0A1-8189-425C-94FE-48C562677659Q47153443-0FA134C0-9FDD-46E2-8B5B-7BA4767E7D1DQ47409996-4E560522-EBD0-4EB3-89B3-EF6308BD2B03Q49544424-492BFA83-C4A5-467B-BE5B-F173AECB14E8Q49805024-B7BD06FC-B7CA-4697-9F4E-3232E2134AD2Q50065221-88568DAA-FF58-44C7-B4E3-7267FF0786F9Q50301832-D38AB70A-46FC-442D-A36B-7E3E11D2F081Q51254914-DD1C14C1-9DEA-4F20-82E4-E50C87BABE95Q51538315-54A1E340-1712-40F5-94B9-56E9E838AC0CQ51706240-CB8D892C-FB8D-4898-8868-DC6D230EFC9CQ55134274-5D7E4FFC-B97E-402E-89AF-64F5BDEAC208Q55234485-8421CD51-2261-4556-A80E-700ABEB3BAF5Q55310990-0B401046-281E-422B-8747-445A332F13DBQ55509868-63B679BA-3B24-4232-8B32-373FB4F881ECQ55515610-6310D2BA-3DD8-46FB-9931-86F51877DA89Q57106074-BB5F1C47-B5BB-44EB-B1B8-9D563B10F541Q57107726-9793C0C9-E9EB-4504-9596-D022A4DA691AQ58099093-35965BE9-E333-450B-B162-53B302C5D216Q58748477-6AD024FA-D512-4E22-B7AB-31C0FC8DAFB5
P2860
Endocrine resistance in breast cancer--An overview and update.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Endocrine resistance in breast cancer--An overview and update.
@ast
Endocrine resistance in breast cancer--An overview and update.
@en
type
label
Endocrine resistance in breast cancer--An overview and update.
@ast
Endocrine resistance in breast cancer--An overview and update.
@en
prefLabel
Endocrine resistance in breast cancer--An overview and update.
@ast
Endocrine resistance in breast cancer--An overview and update.
@en
P2860
P1476
Endocrine resistance in breast cancer--An overview and update.
@en
P2093
J Michael Dixon
John J Tyson
P2860
P304
P356
10.1016/J.MCE.2015.09.035
P478
P577
2015-10-08T00:00:00Z